Literature DB >> 16707447

Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization.

Yong-Jun Yin1, Vered Katz, Zaidoun Salah, Myriam Maoz, Irit Cohen, Beatrice Uziely, Hagit Turm, Sorina Grisaru-Granovsky, Hiromu Suzuki, Rachel Bar-Shavit.   

Abstract

Protease-activated receptor 1 (PAR1) is emerging with distinct assignments in tumor biology. We show that tissue targeted overexpression of hPar1 in mice mammary glands results in precocious hyperplasia, characterized by a dense network of ductal side branching and accelerated proliferation. These glands exhibit increased levels of wnt-4 and wnt-7b and a striking beta-catenin stabilization. Nuclear localization of beta-catenin is observed in hPar1 transgenic mouse tissue sections but not in the wild-type, age-matched counterparts. PAR1 induces beta-catenin nuclear localization also in established epithelial tumor cell lines of intact beta-catenin system (transformed on the background of mismatch repair system; RKO cells). We propose hereby that PAR1-mediated beta-catenin stabilization is taking place primarily via the increase of Wnt expression. Enforced expression of a specific Wnt antagonist family member, secreted frizzled receptor protein 5 (SFRP5), efficiently inhibited PAR1-induced beta-catenin stabilization. Likewise, application of either SFRP2 or SFRP5 on epithelial tumor cells completely abrogated PAR1-induced beta-catenin nuclear accumulation. This takes place most likely via inhibition of Wnt signaling at the level of cell surface (forming a neutralizing complex of "Receptors-SFRP-Wnt"). Furthermore, depletion of hPar1 by small interfering RNA (siRNA) vectors markedly inhibited PAR1-induced Wnt-4. The striking stabilization of beta-catenin, inhibited by SFRPs on one hand and Wnt-4 silencing by hPar1 siRNA on the other hand, points to a novel role of hPar1 in Wnt-mediated beta-catenin stabilization. This link between PAR1 and beta-catenin may bear substantial implications both in developmental and tumor progression processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707447     DOI: 10.1158/0008-5472.CAN-05-4234

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Tissue factor and PAR2 signaling in the tumor microenvironment.

Authors:  Florence Schaffner; Wolfram Ruf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

Review 2.  Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer.

Authors:  Andrea Pia Elste; Iver Petersen
Journal:  J Mol Histol       Date:  2010-06-20       Impact factor: 2.611

3.  Protease-activated receptor-1 (PAR1) acts via a novel Galpha13-dishevelled axis to stabilize beta-catenin levels.

Authors:  Hagit Turm; Myriam Maoz; Vered Katz; Yong-Jun Yin; Steffan Offermanns; Rachel Bar-Shavit
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

Review 4.  Regulation of protease-activated receptor signaling by post-translational modifications.

Authors:  Neil Grimsey; Antonio G Soto; JoAnn Trejo
Journal:  IUBMB Life       Date:  2011-03-24       Impact factor: 3.885

5.  Comprehensive Wnt-related gene expression during cochlear duct development in chicken.

Authors:  Ulrike J Sienknecht; Donna M Fekete
Journal:  J Comp Neurol       Date:  2008-10-01       Impact factor: 3.215

6.  Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.

Authors:  Henri H Versteeg; Florence Schaffner; Marjolein Kerver; Lesley G Ellies; Patricia Andrade-Gordon; Barbara M Mueller; Wolfram Ruf
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

7.  The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.

Authors:  L M Privette Vinnedge; N M Benight; P K Wagh; N A Pease; M A Nashu; J Serrano-Lopez; A K Adams; J A Cancelas; S E Waltz; S I Wells
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

8.  SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer.

Authors:  Y-H Taguchi; Mitsuo Iwadate; Hideaki Umeyama
Journal:  BMC Med Genomics       Date:  2016-08-12       Impact factor: 3.063

Review 9.  Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.

Authors:  Aditi Kothari; Matthew J Flick
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 6.208

10.  Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.

Authors:  Amal Arachiche; María de la Fuente; Marvin T Nieman
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.